still looks expensive given risk With all due respect guys, its not 'mum and dad' punters who are selling. There are 500k sell orders going through at 14c (already one gone, if the present one goes, expect another). This is insto/top 20 selling.
Cash asset backing is irrelevant since ABI are channelling all their cash to BEL. Cash will be gone within six months, so the question becomes 'Can ABI attract further investment?' Even if the test bed demo in 6 months is sucessful, I think further intso investment in ABI is unlikely. Amongst analysts, ABI now has one of the worst reputations in the Aust biotech sector. And the company has now licenced off its technology (in all its potential applications) to Dow and Genencor, so there would be no point in big pharma buying ABI. Indeed, in a sad way, it is actually in Dow and Genencor's interest for ABI to fold. With new market-ready products based on the silicon biosensor still 2-3 years away, ABI have run out of time even to receive licensing revenue. I think the silicon biosensor will *eventually* be a great success, but any intelligent investor who wants to reap the potential rewards of the ICS platform would invest in Dow and Genencor, not ABI.
ABI
ambri limited
